While the authors reported reduced liver damage, steatosis, and fibrosis upon NLRP6 overexpression [13], we did not observe any alteration in these disease characteristics upon abrogation of endogenous NLRP6 activity in our long-term chronic-plus-binge model of ALD. The gene discussed is NLRP6; the disease is steatosis.